BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)
CUSIP: 09075P105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 26,011,000
- Total 13F shares
- 14,875
- Share change
- +14,875
- Total reported value
- $5,503
- Price per share
- $0.37
- Number of holders
- 1
- Value change
- +$5,503
- Number of buys
- 1
Quarterly Holders Quick Answers
What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09075P105:
Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Rashmi Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,554,945
|
$187,267,747 | — | 03 Apr 2023 | |
| Vipin Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,554,945
|
$187,267,747 | — | 03 Apr 2023 | |
| Indu R. Gupta |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,550,396
|
$187,168,169 | — | 03 Apr 2023 | |
| Tarun K. Gupta |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,550,396
|
$187,168,169 | — | 03 Apr 2023 | |
| Suganthi Balasubramanian |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,750
|
$187,110,248 | — | 03 Apr 2023 | |
| Anita Jain |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,300
|
$187,100,398 | — | 03 Apr 2023 | |
| Diwakar Jain |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,300
|
$187,100,398 | — | 03 Apr 2023 | |
| Krishnan Nandabalan |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
8,840,750
mixed-class rows
|
$187,088,358 | — | 06 Apr 2023 | |
| Akrati Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Alka Sood |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Anesha Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Bina Jatin Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| BioXcel Holdings, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 25 Jun 2021 | |
| BioXcel LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 25 Jun 2021 | |
| Jatin Markand Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Krunal Dilip Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Marshal D. Gibson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Michael James Aiello |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Pardeep Kumar Sood |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
288,131
|
$564,737 | -$9,229,922 | 31 Mar 2025 | |
| Murchinson Ltd. |
13F
|
Company |
0.62%
|
136,076
|
$276,234 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.47%
|
101,778
|
$206,609 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.11%
|
24,794
|
$50,332 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.11%
|
23,241
|
$47,179 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
22,062
|
$44,793 | — | 31 Mar 2025 | |
| Beacon Pointe Advisors, LLC |
13F
|
Company |
0.09%
|
18,845
|
$38,255 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.09%
|
18,824
|
$38,213 | — | 31 Mar 2025 | |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
|
Oaktree Capital Holdings, LLC |
2.7%
|
170,230
|
$28,939 | -$434,154 | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.06%
|
12,293
|
$24,955 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.05%
|
10,666
|
$22,000 | — | 31 Mar 2025 | |
| Matthew T. Wiley |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
28,386
mixed-class rows
|
$20,056 | — | 17 Sep 2024 | |
| Vincent O'Neill |
3/4/5
|
Executive Vice President, Chief of Product Development and Medical Officer |
—
mixed-class rows
|
24,438
mixed-class rows
|
$7,975 | — | 14 Dec 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
1,910
|
$3,877 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.01%
|
1,884
|
$3,823 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
1,766
|
$3,585 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
1,519
|
$3,084 | — | 31 Mar 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.01%
|
1,273
|
$2,584 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
851
|
$1,728 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0%
|
237
|
$481 | — | 31 Mar 2025 | |
| AllSquare Wealth Management LLC |
13F
|
Company |
0%
|
175
|
$355 | — | 31 Mar 2025 | |
| Washington Trust Advisors, Inc. |
13F
|
Company |
0%
|
160
|
$325 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
152
|
$309 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
116
|
$235 | — | 31 Mar 2025 | |
| Parkside Financial Bank & Trust |
13F
|
Company |
0%
|
112
|
$228 | — | 31 Mar 2025 | |
| Zurcher Kantonalbank (Zurich Cantonalbank) |
13F
|
Company |
0%
|
103
|
$209 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
44
|
$89 | — | 31 Mar 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0%
|
31
|
$63 | — | 31 Mar 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0%
|
27
|
$54 | — | 31 Mar 2025 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0%
|
21
|
$43 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
11
|
$22 | — | 31 Mar 2025 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
0
Q2 2025 holders
1
Holder diff
1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.